Arlene L. Chow
At the outset, Arlene frames patent litigation matters from the perspective of the judge or the jury in order to achieve the best solutions for clients. Leveraging her lead trial attorney and biochemistry experience, she dives deeply into the relevant science and underlying facts before extracting key case themes for development with the case record.
Arlene loves engaging with the in-house and external experts on the science, and then simplifying that highly technical information in a way that is easy to digest.
Arlene has applied this pragmatic approach as lead attorney in district court hearings and trials, federal circuit arguments, and inter partes review hearings, as well as when engaging in patent due diligence in support of the purchase or sale of drugs or their royalty streams.
Arlene primarily focuses on the life sciences, having worked on matters implicating small molecule and biologic drugs for the treatment of ulcers, depression, schizophrenia, pneumonia, hemophilia, pain, menopause, anaphylaxis, glaucoma, multiple sclerosis, hypertension, diabetes, COPD, overactive bladder, asthma, overactive thyroid, arthritis, irritable bowel, urinary tract infections, hepatitis, and skin, lung, and prostate cancer. Arlene has also handled matters involving a wide variety of medical devices and dosage forms, including auto-injectors, orally disintegrating and buccal tablets, transdermal patches, spinal devices, sprays, gels, inhalers, gastric bands, and nebulizers.
As lead counsel, obtained a permanent injunction for a leading Japanese pharmaceutical firm in a bench trial on infringement and validity.
On behalf of patent owner Depomed, obtained favorable written decisions in inter partes review proceedings involving controlled release gastric retentive technology.
Obtained noninfringement, invalidity, and inequitable conduct determinations at bench and jury trials for Photoscribe, a laser manufacturer.
Obtained noninfringement determinations at ITC bench trial for Qisda and BenQ, LCD monitor manufacturers.
As lead counsel, representing Santen and Asahi Glass in multiple Hatch-Waxman litigations involving glaucoma drug.
Obtained summary judgment of invalidity determination for Millennium in relation to urine drug testing protocols.
Intellectual Property Litigation
New York Super Lawyers
Rising Stars, Intellectual Property Litigation
New York Super Lawyers
Latest thinking and events
21 June 2016
Hogan Lovells Events
17 February 2016
10 November 2014